Akebia Therapeutics Earnings Calls

Q1 2025 Beat
$0.0300 (200.00%)
Release date May 08, 2025
EPS estimate -$0.0300
EPS actual $0.0300
EPS Surprise 200.00%
Revenue estimate 50.8M
Revenue actual 57.336M
Revenue Surprise 12.87%
Q4 2024 Missed
-$0.100 (-100.00%)
Release date Mar 13, 2025
EPS estimate -$0.0500
EPS actual -$0.100
EPS Surprise -100.00%
Revenue estimate 37.414M
Revenue actual 46.497M
Revenue Surprise 24.28%
Q3 2024 Missed
-$0.100 (-100.00%)
Release date Nov 07, 2024
EPS estimate -$0.0500
EPS actual -$0.100
EPS Surprise -100.00%
Revenue estimate 40.912M
Revenue actual 37.428M
Revenue Surprise -8.51%
Q2 2024 Beat
-$0.0400 (33.33%)
Release date Aug 08, 2024
EPS estimate -$0.0600
EPS actual -$0.0400
EPS Surprise 33.33%
Revenue estimate 49.45M
Revenue actual 43.648M
Revenue Surprise -11.73%

Last 4 Quarters for Akebia Therapeutics

Below you can see how AKBA performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.

Q2 2024 Beat
Release date Aug 08, 2024
Fiscal end date Jun 30, 2024
Price on release $1.19
EPS estimate -$0.0600
EPS actual -$0.0400
EPS surprise 33.33%
Date Price
Aug 02, 2024 $1.25
Aug 05, 2024 $1.19
Aug 06, 2024 $1.23
Aug 07, 2024 $1.11
Aug 08, 2024 $1.19
Aug 09, 2024 $1.11
Aug 12, 2024 $1.23
Aug 13, 2024 $1.34
Aug 14, 2024 $1.35
4 days before -4.80%
4 days after 13.45%
On release day -6.72%
Change in period 8.00%
Q3 2024 Missed
Release date Nov 07, 2024
Fiscal end date Sep 30, 2024
Price on release $1.87
EPS estimate -$0.0500
EPS actual -$0.100
EPS surprise -100.00%
Date Price
Nov 01, 2024 $1.69
Nov 04, 2024 $1.85
Nov 05, 2024 $1.86
Nov 06, 2024 $2.00
Nov 07, 2024 $1.87
Nov 08, 2024 $1.94
Nov 11, 2024 $1.99
Nov 12, 2024 $1.95
Nov 13, 2024 $1.92
4 days before 10.65%
4 days after 2.67%
On release day 3.74%
Change in period 13.61%
Q4 2024 Missed
Release date Mar 13, 2025
Fiscal end date Dec 31, 2024
Price on release $1.69
EPS estimate -$0.0500
EPS actual -$0.100
EPS surprise -100.00%
Date Price
Mar 07, 2025 $1.90
Mar 10, 2025 $1.86
Mar 11, 2025 $1.93
Mar 12, 2025 $1.93
Mar 13, 2025 $1.69
Mar 14, 2025 $2.26
Mar 17, 2025 $2.40
Mar 18, 2025 $2.55
Mar 19, 2025 $2.84
4 days before -11.05%
4 days after 68.05%
On release day 33.73%
Change in period 49.47%
Q1 2025 Beat
Release date May 08, 2025
Fiscal end date Mar 30, 2025
Price on release $2.62
EPS estimate -$0.0300
EPS actual $0.0300
EPS surprise 200.00%
Date Price
May 02, 2025 $2.45
May 05, 2025 $2.34
May 06, 2025 $2.32
May 07, 2025 $2.46
May 08, 2025 $2.62
May 09, 2025 $2.55
4 days before 6.94%
4 days after -2.67%
On release day -2.67%
Change in period 4.08%

Akebia Therapeutics Earnings Call Transcript Summary of Q1 2025

Key Points from Akebia's Q1 2025 Earnings Call

  • Strong Product Launch:
    • Akebia reported US net product revenues of $12 million for Vafseo, surpassing guidance of $10-11 million.
    • The launch is being positively received, particularly among nephrologists seeking new treatment options for CKD patients on dialysis.
  • Commercial Strategy:
    • Akebia's team is actively educating dialysis providers and prescribers about Vafseo, contributing to early adoption.
    • The company has commercial contracts that cover almost 100% of dialysis patients.
    • Initial sales primarily stem from small to mid-sized dialysis organizations, with expectations for larger dialysis organizations (LDOs) to begin operationalizing Vafseo later in the year.
  • Ongoing Studies and Trials:
    • The VOICE study is progressing well, with about 75% of the desired 2,200 patients enrolled, which may yield critical data on patient outcomes.
    • Plans to initiate the Phase III VALOR trial for non-dialysis CKD patients are on track for H2 2025, pending discussions with the FDA.
  • Financial Performance:
    • Total revenues increased to $57.3 million for Q1 2025, driven by Vafseo and Auryxia sales.
    • Auryxia net product revenues rose to $43.8 million despite losing IP exclusivity, contributing to overall growth.
    • Net income for the quarter was $6.1 million, a significant improvement from a $18 million loss in the previous year.
  • Inventory and Supply Chain Management:
    • Inventory levels are currently stable at about four weeks, with expectations to adjust based on future demand.
    • The distribution network for LDOs has been enhanced to ensure efficient delivery of products to patients.
  • Reimbursement and Market Access:
    • There are positive trends in reimbursement, with an estimated 80% of prescriptions covered under Medicare Fee-for-Service, with growing acceptance from Medicare Advantage plans.
    • Encouraging signs indicate that prescribers are eager to use Vafseo, regardless of health plan.
  • Future Outlook:
    • Continued focus on expanding prescriber bases and increasing prescription volumes.
    • Plans to drive Vafseo towards becoming a standard treatment for anemia in CKD patients.
    • Additional updates on progress are slated for the Q2 call in August.

Investment Considerations:

Investors should take note of Akebia's strong launch performance and strategic direction, particularly with respect to expanding market access for Vafseo and planning for future clinical trials. The company's financial improvement and effective management of inventory and distribution signal a robust operational position, while ongoing studies may enhance product credibility and market acceptance. However, investors should remain aware of potential competitive dynamics, especially with generic entries affecting Auryxia and the evolving landscape of reimbursement policies.

Akebia Therapeutics Earnings History

Earnings Calendar

FAQ

When is the earnings report for AKBA?
Akebia Therapeutics (AKBA) has scheduled its earnings report for Aug 14, 2025 before the markets open.

What is the AKBA price-to-earnings (P/E) ratio?
AKBA P/E ratio as of May 09, 2025 (TTM) is -7.75.

What is the AKBA EPS forecast?
The forecasted EPS (Earnings Per Share) for Akebia Therapeutics (AKBA) for the first fiscal quarter 2025 is -$0.0300.

What are Akebia Therapeutics's retained earnings?
On its balance sheet, Akebia Therapeutics reported retained earnings of $57.34 million for the latest quarter ending Mar 30, 2025.

What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.

Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.

What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
Click to get the best stock tips daily for free!
ABOUT AKEBIA THERAPEUTICS
Akebia Therapeutics
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citra...
GOLDEN STAR
Ticker Change Signal Date
BAX
$30.72
0.586% May 07
HBM
$7.41
4.05% May 05
P
PENG
$17.23
2.21% May 05
A
AORT
$23.77
21.62% May 05
PODD
$257.01
20.88% May 02

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE